Gamitrinib TPP is a mitochondrial targeted HSP90 inhibitor exhibiting potent anti-cancer activity. Additionally, Gamitrinib TPP functions as a mitochondrial matrix inhibitor by targeting Gamitrinib (GA).

Exposure to 15-20 μM of Gamitrinib TPP for 16 hours effectively induces death in both patient-derived and cultured glioblastoma cell lines through a process characteristic of mitochondrial apoptosis. This includes a loss of mitochondrial inner membrane potential, cytochrome c release into the cytosol, activation of caspase-9, caspase-3, and caspase-7, and cellular annexin V reactivity. The selectivity of Gamitrinib TPP is attributed to the presence of Hsp90s in the mitochondria of tumor cells, but not in normal tissues, thereby sparing normal fetal human astrocytes (FHAS) from damage. In contrast, 17-AAG, which is not targeted to any subcellular compartment, shows no discernible effects on either normal or tumor cells under similar conditions.

Administering two cycles of intracranial TRAIL alongside systemic G-TPP effectively inhibits the growth of established glioblastomas without causing significant weight loss in the animals. Examination of brain sections from these treated mice, unlike those receiving only single-agent treatment, reveals a decrease in tumor cell proliferation, internucleosomal DNA fragmentation, and caspase-3 activity, indicating a significant induction of apoptosis in vivo.